Barinthus Biotherapeutics plc. 8-K

What Happened
Barinthus Biotherapeutics plc (BRNS) filed an 8‑K reporting results of its July 2, 2026 Annual General Meeting and disclosing a Nasdaq notice extending the company’s bid‑price compliance period. At the AGM the company established a quorum (17,549,280 of 40,848,893 ordinary shares entitled to vote) and elected its director nominees (Karen T. Dawes and Anne M. Phillips) and re‑appointed PricewaterhouseCoopers LLP as its U.K. statutory auditors; all matters submitted were approved. Separately, Nasdaq informed the company that it granted an additional 180‑day compliance period to regain the $1.00 ADS minimum bid price, extending the deadline to December 28, 2026, and transferred the ADS listing from the Nasdaq Global Market to the Nasdaq Capital Market effective July 2, 2026.

Key Details

• Shares entitled to vote: 40,848,893; shares present or represented by valid proxy: 17,549,280 (quorum established).
• Director election votes: Karen T. Dawes — 17,454,768 for / 43,382 against / 50,005 withheld; Anne M. Phillips — 17,494,160 for / 3,995 against / 50,000 withheld.
• Auditor votes: PwC re‑appointment as U.K. statutory auditors — 17,496,815 for / 1,115 against / 50,350 withheld; ratification as independent registered public accounting firm — 17,496,815 for / 1,015 against / 50,450 withheld.
• Nasdaq history and extension: initial notice received Dec 30, 2025 (deadline June 29, 2026); Nasdaq granted an additional 180 days to Dec 28, 2026 and moved listing to the Nasdaq Capital Market effective July 2, 2026. The company may pursue measures (including a reverse stock split) to regain the $1.00 ADS bid price; failure to comply could lead to delisting, subject to a Nasdaq hearings panel appeal.

Why It Matters
The AGM results confirm board continuity and auditor reappointment, which are routine governance items investors watch. The Nasdaq extension and market transfer are material for shareholders because they reflect a continued deficiency in the ADS trading price and create a clear deadline (Dec 28, 2026) to regain compliance. If the ADSs do not meet the $1.00 minimum bid requirement within the extension period, Nasdaq could initiate delisting proceedings—potentially affecting liquidity and market access—although the company can seek remedies (including a reverse split) or appeal any delisting decision.